Cytek Biosciences (CTKB) Gross Margin (2020 - 2026)
Cytek Biosciences (CTKB) posted Gross Margin of 48.16% for Q1 2026, down 9.0% on a QoQ basis from 52.92% in Q4 2025, and down 46.0% year-over-year from 89.18% in Q1 2025.
Cytek Biosciences (CTKB) Gross Margin (2020 - 2026) Analysis & Trends
Cytek Biosciences' Gross Margin history runs 7 years deep, the most recent figure standing at 48.16% for Q1 2026.
- Quarterly Gross Margin fell 46.0% year-over-year to 48.16% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 51.7% (down 324.0% YoY) and the FY2025 annual result came in at 51.84%, down 358.0% from the prior year.
- Gross Margin was 48.16% for Q1 2026 at Cytek Biosciences, down from 52.92% in the prior quarter.
- Across five years, Gross Margin topped out at 66.36% in Q3 2022 and bottomed at 48.16% in Q1 2026.
- A 5-year average of 55.77% and a median of 56.62% in 2023 frame the typical range for Gross Margin.
- Annual changes were most pronounced in 2022 — Gross Margin jumped 447 bps — and 2023, when it tumbled 974 bps.
- Cytek Biosciences' Gross Margin stood at 60.77% in 2022, then slipped by 7 bps to 56.75% in 2023, then rose by 3 bps to 58.55% in 2024, then decreased by 10 bps to 52.92% in 2025, then dropped by 9 bps to 48.16% in 2026.
- Business Quant data shows CTKB's Gross Margin at 48.16% in Q1 2026, 52.92% in Q4 2025, and 52.69% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 56.20% |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 63.29% |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 65.35% |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 69.46% |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 78.01% |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 62.95% |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 45.22% |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 38.53% |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Cytek Biosciences | 586.89 Mn | 521.19 Mn | 21.25 Mn | 48.16% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 48.16% |
| Dec 31, 2025 | 52.92% |
| Sep 30, 2025 | 52.69% |
| Jun 30, 2025 | 52.34% |
| Mar 31, 2025 | 48.62% |
| Dec 31, 2024 | 58.55% |
| Sep 30, 2024 | 56.32% |
| Jun 30, 2024 | 54.56% |
| Mar 31, 2024 | 51.30% |
| Dec 31, 2023 | 56.75% |
| Sep 30, 2023 | 56.62% |
| Jun 30, 2023 | 56.67% |
| Mar 31, 2023 | 56.72% |
| Dec 31, 2022 | 60.77% |
| Sep 30, 2022 | 66.36% |
| Jun 30, 2022 | 61.16% |
| Mar 31, 2022 | 57.54% |
| Dec 31, 2021 | 60.77% |
| Sep 30, 2021 | 61.89% |
| Jun 30, 2021 | 64.93% |